Corient Private Wealth LP Purchases 1,647,315 Shares of Gossamer Bio, Inc. $GOSSDefense World · Sep 28, 2026
Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial HypertensionBusiness Wire · Sep 23, 2026
Hsbc Holdings PLC Increases Stock Position in Gossamer Bio, Inc. $GOSSDefense World · Sep 17, 2026
Gossamer Bio Appoints Greg Ciongoli to Board of DirectorsBusiness Wire · Sep 16, 2026
Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock SplitGuruFocus · Sep 11, 2026
Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock SplitBusiness Wire · Sep 11, 2026Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2026 | -$9.87 | -$6.40 | Beat |
| May 18, 2026 | -$13.60 | -$0.20 | Beat |
| Mar 18, 2026 | -$16.00 | -$0.21 | Beat |
| Nov 6, 2025 | -$15.20 | -$16.80 | Miss |
| Aug 11, 2025 | -$14.40 | -$0.17 | Beat |
| May 15, 2025 | -$15.20 | -$12.80 | Beat |